NCT03389906

Brief Summary

The aim of this study is to use gold particles as a model compound to modulate specifically and selectively the function of macrophages and mast cells and investigate how this modulates pain and pain sensitization in the osteoarthritic knee assessed by mechanistic pain assessment technologies

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2017

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

December 27, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 4, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

August 12, 2021

Status Verified

August 1, 2021

Enrollment Period

1 year

First QC Date

December 27, 2017

Last Update Submit

August 9, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • WOMAC

    The WOMAC\[6\] is a subject-rated instrument that measures Osteoarthritis (OA)

    8 weeks, 2 years

Secondary Outcomes (5)

  • Quantitative sensory testing

    8 weeks

  • Weekly pain diary

    8 weeks

  • Inflammatory markers

    8 weeks

  • PainDetect questionnaire (PD-Q

    8 weeks, 2 years

  • Global Rating of Change Scale

    2 years

Study Arms (1)

Gold

EXPERIMENTAL

Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).

Other: Gold

Interventions

GoldOTHER

Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.

Gold

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Knee OA diagnosed based on the American College of Rheumatology criteria, KL (Kellgren-Lawrence) X-ray grade ≧ 2, pain for \> 3months, maximal pain intensity VAS (visual analogue scale) ≧ 5 (0-10 scale) for the most painful knee during the last week. Knee joint effusion that can be aspirated

You may not qualify if:

  • Pregnancy
  • Drug addiction defined as the use of cannabis, opioids or other drugs
  • Previous neurologic, musculoskeletal or mental illnesses
  • Lack of ability to cooperate
  • Current use of medications that may affect the trial e.g. analgesics, anti-inflammatory drugs
  • Recent history of acute pain affecting the lower limb and/or trunk
  • Past history of a chronic pain condition
  • Participation in other pain trials throughout the study period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University Hospital

Aalborg, 9000, Denmark

Location

Related Publications (38)

  • Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003 Dec;106(3):337-345. doi: 10.1016/j.pain.2003.08.001.

    PMID: 14659516BACKGROUND
  • Andrew D, Greenspan JD. Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol. 1999 Nov;82(5):2649-56. doi: 10.1152/jn.1999.82.5.2649.

  • Arendt-Nielsen L, Egsgaard LL, Petersen KK, Eskehave TN, Graven-Nielsen T, Hoeck HC, Simonsen O. A mechanism-based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levels. Eur J Pain. 2015 Nov;19(10):1406-17. doi: 10.1002/ejp.651. Epub 2014 Dec 29.

  • Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. Pain. 2010 Jun;149(3):573-581. doi: 10.1016/j.pain.2010.04.003. Epub 2010 Apr 24.

  • Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-1644. doi: 10.1097/j.pain.0000000000000562.

  • Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. Curr Osteoporos Rep. 2015 Aug;13(4):225-34. doi: 10.1007/s11914-015-0276-x.

  • Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833-40.

  • Christensen MM, Danscher G, Ellermann-Eriksen S, Schionning JD, Rungby J. Autometallographic silver-enhancement of colloidal gold particles used to label phagocytic cells. Histochemistry. 1992;97(3):207-11. doi: 10.1007/BF00267629.

  • Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;1997(2):CD000520. doi: 10.1002/14651858.CD000520.

  • Courtney CA, Kavchak AE, Lowry CD, O'Hearn MA. Interpreting joint pain: quantitative sensory testing in musculoskeletal management. J Orthop Sports Phys Ther. 2010 Dec;40(12):818-25. doi: 10.2519/jospt.2010.3314. Epub 2010 Oct 22.

  • Danscher G. In vivo liberation of gold ions from gold implants. Autometallographic tracing of gold in cells adjacent to metallic gold. Histochem Cell Biol. 2002 May;117(5):447-52. doi: 10.1007/s00418-002-0400-8. Epub 2002 Apr 13.

  • Danscher G, Stoltenberg M. Silver enhancement of quantum dots resulting from (1) metabolism of toxic metals in animals and humans, (2) in vivo, in vitro and immersion created zinc-sulphur/zinc-selenium nanocrystals, (3) metal ions liberated from metal implants and particles. Prog Histochem Cytochem. 2006;41(2):57-139. doi: 10.1016/j.proghi.2006.06.001. Epub 2006 Aug 7.

  • Forestier J. Rheumatoid arthritis and its treatment by gold salts. The lancet 1934;224:646-648.

    RESULT
  • Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006 Oct;22(10):1911-20. doi: 10.1185/030079906X132488.

  • Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN. Inflammatory predictors of ongoing pain 2 years following knee replacement surgery. Knee. 2013 Oct;20(5):316-8. doi: 10.1016/j.knee.2012.10.015. Epub 2012 Nov 14.

  • Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 2012 Sep;64(9):2907-16. doi: 10.1002/art.34466.

  • Guy W, Bonato RR. Manual for the ECDEU assessment battery. : US Department of Health, Education, and Welfare, National Institute of Mental Health, 1970

    RESULT
  • Jaeger GT, Larsen S, Soli N, Moe L. Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis. Acta Vet Scand. 2007 Mar 23;49(1):9. doi: 10.1186/1751-0147-49-9.

  • Jinks C, Jordan K, Croft P. Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 2007 May;46(5):877-81. doi: 10.1093/rheumatology/kem013. Epub 2007 Feb 17.

  • Jones G, Brooks PM. Injectable gold compounds: an overview. Br J Rheumatol. 1996 Nov;35(11):1154-8. doi: 10.1093/rheumatology/35.11.1154.

  • Kean TA. Rheumatoid Arthritis and Gold Salts Therapy. Ulster Med J. 1934 Oct;3(4):284-9. No abstract available.

  • Labens R, Lascelles BD, Charlton AN, Ferrero NR, Van Wettere AJ, Xia XR, Blikslager AT. Ex vivo effect of gold nanoparticles on porcine synovial membrane. Tissue Barriers. 2013 Apr 1;1(2):e24314. doi: 10.4161/tisb.24314.

  • Larsen A, Kolind K, Pedersen DS, Doering P, Pedersen MO, Danscher G, Penkowa M, Stoltenberg M. Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury. Histochem Cell Biol. 2008 Oct;130(4):681-92. doi: 10.1007/s00418-008-0448-1. Epub 2008 Jun 10.

  • Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J; METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005 May;52(5):1360-70. doi: 10.1002/art.21018.

  • Leonaviciene L, Kirdaite G, Bradunaite R, Vaitkiene D, Vasiliauskas A, Zabulyte D, Ramanaviciene A, Ramanavicius A, Asmenavicius T, Mackiewicz Z. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Medicina (Kaunas). 2012;48(2):91-101. Epub 2012 Apr 5.

  • Lie KI, Jaeger G, Nordstoga K, Moe L. Inflammatory response to therapeutic gold bead implantation in canine hip joint osteoarthritis. Vet Pathol. 2011 Nov;48(6):1118-24. doi: 10.1177/0300985810381910. Epub 2010 Sep 22.

  • Meier FM, Frerix M, Hermann W, Muller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy. 2013 Sep;5(9):955-74. doi: 10.2217/imt.13.94.

  • Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998 Oct;37(10):1060-8. doi: 10.1093/rheumatology/37.10.1060.

  • Petersen KK, Arendt-Nielsen L, Simonsen O, Wilder-Smith O, Laursen MB. Presurgical assessment of temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. Pain. 2015 Jan;156(1):55-61. doi: 10.1016/j.pain.0000000000000022.

  • Petersen KK, Siebuhr AS, Graven-Nielsen T, Simonsen O, Boesen M, Gudbergsen H, Karsdal M, Bay-Jensen AC, Arendt-Nielsen L. Sensitization and Serological Biomarkers in Knee Osteoarthritis Patients With Different Degrees of Synovitis. Clin J Pain. 2016 Oct;32(10):841-8. doi: 10.1097/AJP.0000000000000334.

  • Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford). 2002 Feb;41(2):196-204. doi: 10.1093/rheumatology/41.2.196.

  • Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M, Vogel U, Larsen A, Kreyling W, Wallin H. Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation. Chem Cent J. 2009 Nov 20;3:16. doi: 10.1186/1752-153X-3-16.

  • Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol. 2000 Feb;27(2):523-9.

  • Seifert O, Matussek A, Sjogren F, Geffers R, Anderson CD. Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucytotic gold ions. J Inflamm (Lond). 2012 Nov 9;9(1):43. doi: 10.1186/1476-9255-9-43.

  • Sturmer T, Brenner H, Koenig W, Gunther KP. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis. 2004 Feb;63(2):200-5. doi: 10.1136/ard.2003.007674.

  • Williams HJ. Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1988 Sep;16:9-13.

  • Wylde V, Sayers A, Lenguerrand E, Gooberman-Hill R, Pyke M, Beswick AD, Dieppe P, Blom AW. Preoperative widespread pain sensitization and chronic pain after hip and knee replacement: a cohort analysis. Pain. 2015 Jan;156(1):47-54. doi: 10.1016/j.pain.0000000000000002.

  • Rasmussen S, Petersen KK, Aboo C, Andersen JS, Skjoldemose E, Jorgensen NK, Stensballe A, Arendt-Nielsen L. Intra-articular injection of gold micro-particles with hyaluronic acid for painful knee osteoarthritis. BMC Musculoskelet Disord. 2024 Mar 12;25(1):211. doi: 10.1186/s12891-024-07321-4.

MeSH Terms

Conditions

Inflammation

Interventions

Gold

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsTransition ElementsMetals

Study Officials

  • Lars Arendt-Nielsen, MD, PhD

    Aalborg University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: Pilot study
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor Head of Department of Clinical Medicine

Study Record Dates

First Submitted

December 27, 2017

First Posted

January 4, 2018

Study Start

December 1, 2017

Primary Completion

December 1, 2018

Study Completion

December 1, 2020

Last Updated

August 12, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will share

Inflammatory markers may be shared with other researchers

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
After publication information is available.
Access Criteria
At the reasonable request to Sten Rasmusssen. (sten.rasmussen@rn.dk;s\ rasmussen@dcm.aau.dk

Locations